Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

San Francisco Veterans Affairs Medical Center

Status: Unknown

Conditions: Hepatocellular Carcinoma

Treatments: Procedure: MRI Scan of the Liver enhanced with Eovist

Study type: Observational

Funder types: Other; Other U.S. Federal agency; Industry

Identifiers

NCT01341132

10-03278

Details and patient eligibility

About

This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Alpha-feto protein > 400 ng / mL or
• prior ultrasound with mass suspicious for hepatic malignancy or.
• clinical risk of hepatocellular carcinoma or
• prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Exclusion criteria

• Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study
• Previous diagnosis of hepatic malignancy
• Any conditions that would discount the ability to have an MRI scan

Trial design

75 participants in 1 patient group

Suspected Liver Disease

Description:

1. Alpha-feto protein \> 400 ng / mL or 2. prior ultrasound with mass suspicious for hepatic malignancy or. 3. clinical risk of hepatocellular carcinoma or 4. prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Treatment:

Procedure: MRI Scan of the Liver enhanced with Eovist